HSINCHU, Oct. 3, 2015 /PRNewswire/ -- JHL Biotech (TWEM: 6540), an emerging biosimilars company incorporated in Cayman Islands and based in Taiwan and China, announced today it has been publicly listed on the Taiwan Emerging Stock Board, effective September 17, 2015.
JHL Biotech's current capital value is $1.89 billion in New Taiwan dollars. The Taiwan Emerging Stock Board (ESB) is an introductory listing for companies before listing on Taipei Exchange (TPEx) or the Taiwan Stock Exchange (TWSE).
JHL Biotech's public offering is made by certain shareholders selling a portion of their current holdings of JHL Biotech's common stock. Yuanta Securities is the lead underwriter. Investors can contact JHL Biotech or buy directly from the Taiwan Emerging Stock Board.
About JHL Biotech
JHL Biotech is an emerging biopharmaceuticals company founded by a group of biotech veterans with decades of manufacturing experience. JHL Biotech has been backed by a consortium of top-tier venture capital firms including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital and China Development Industrial Bank (CDIB). JHL Biotech's mission is to provide affordable world-class medicines to more patients worldwide. JHL Biotech concentrates on developing new protein drugs and biosimilars that comply with international standards. JHL Biotech has capability on cell line development, cell culture, purification, formulation, stability test and GMP manufacturing. In addition to in-house research and development, JHL Biotech has signed co-development agreements with four international medical companies.
A key component for JHL in achieving its vision is its state-of-the-art facilities that are built in compliance with United States, European Union and International Conference on Harmonisation (ICH) current good manufacturing practices (cGMP) regulations and guidelines. The company has facilities in Taiwan that support all pre-clinical and early clinical activities for biologics development. JHL is currently building facilities to support commercial manufacturing in Wuhan, China, with an expected completion within two years. With this comprehensive infrastructure in place, JHL Biotech is uniquely positioned to deliver manufacturing solutions to its worldwide partners. For more information about the company, visit www.jhlbiotech.com.